Christopher P. Guise

2.1k total citations
51 papers, 1.6k citations indexed

About

Christopher P. Guise is a scholar working on Molecular Biology, Cancer Research and Biotechnology. According to data from OpenAlex, Christopher P. Guise has authored 51 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 25 papers in Cancer Research and 17 papers in Biotechnology. Recurrent topics in Christopher P. Guise's work include Cancer, Hypoxia, and Metabolism (25 papers), Cancer Research and Treatments (17 papers) and Virus-based gene therapy research (9 papers). Christopher P. Guise is often cited by papers focused on Cancer, Hypoxia, and Metabolism (25 papers), Cancer Research and Treatments (17 papers) and Virus-based gene therapy research (9 papers). Christopher P. Guise collaborates with scholars based in New Zealand, United Kingdom and United States. Christopher P. Guise's co-authors include Adam V. Patterson, William R. Wilson, Jeff B. Smaill, Alexandra M. Mowday, Maria R. Abbattista, Amir Ashoorzadeh, Eva I. Hyde, Peter F. Searle, David F. Ackerley and Jane I. Grove and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Biochemistry.

In The Last Decade

Christopher P. Guise

51 papers receiving 1.6k citations

Peers

Christopher P. Guise

BIOTE

ONCOL

Dean C. Singleton New Zealand

Melissa Millard United States

Yiting Qiao China

Olga Greco United Kingdom

Wenhua Tang United States

Mark Olsen United States

Mark R. Bray Canada

Piyush Kumar Canada

Susan M. Pullen New Zealand

Kun Chen China

Dean C. Singleton New Zealand

Christopher P. Guise

1.0k ×1.2

367 ×0.6

102 ×0.3

BIOTE

215 ×0.7

272 ×1.1

ONCOL

Citations per year, relative to Christopher P. Guise Christopher P. Guise (= 1×) peers Dean C. Singleton

Countries citing papers authored by Christopher P. Guise

Since Specialization

Citations

This map shows the geographic impact of Christopher P. Guise's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher P. Guise with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher P. Guise more than expected).

Fields of papers citing papers by Christopher P. Guise

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher P. Guise. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher P. Guise. The network helps show where Christopher P. Guise may publish in the future.

Co-authorship network of co-authors of Christopher P. Guise

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher P. Guise. A scholar is included among the top collaborators of Christopher P. Guise based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher P. Guise. Christopher P. Guise is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ashoorzadeh, Amir, Alexandra M. Mowday, Christopher P. Guise, et al.. (2022). Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications. Pharmaceuticals. 15(2). 185–185. 3 indexed citations

Singleton, Dean C., Alexandra M. Mowday, Christopher P. Guise, et al.. (2021). Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit. Cancer Gene Therapy. 29(7). 1021–1032. 6 indexed citations

Mowday, Alexandra M., Janine N. Copp, Sophie P. Syddall, et al.. (2020). E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications. Theranostics. 10(23). 10548–10562. 21 indexed citations

Guise, Christopher P., et al.. (2019). Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study. Bioorganic & Medicinal Chemistry Letters. 29(10). 1215–1219. 7 indexed citations

Zhang, Zhang, Christopher P. Guise, Xueqiang Li, et al.. (2017). 2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors. ACS Medicinal Chemistry Letters. 8(5). 543–548. 34 indexed citations

Li, Xueqiang, Christopher P. Guise, Y. Yosaatmadja, et al.. (2017). 2-Oxo-3, 4-dihydropyrimido[4, 5- d ]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors. European Journal of Medicinal Chemistry. 135. 531–543. 24 indexed citations

Abbattista, Maria R., Stephen M. F. Jamieson, Yongchuan Gu, et al.. (2015). Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma. Cancer Biology & Therapy. 16(4). 610–622. 27 indexed citations

Wang, Jingli, Christopher P. Guise, Gabi U. Dachs, et al.. (2014). Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5. Biochemical Pharmacology. 91(4). 436–446. 29 indexed citations

Green, Laura K., Sophie P. Syddall, Christopher P. Guise, et al.. (2013). Pseudomonas aeruginosa NfsB and nitro-CBI-DEI – a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy. Molecular Cancer. 12(1). 58–58. 15 indexed citations

10.

Gu, Yongchuan, Frederik B. Pruijn, Jeff B. Smaill, et al.. (2013). Zinc Finger Nuclease Knock-out of NADPH:Cytochrome P450 Oxidoreductase (POR) in Human Tumor Cell Lines Demonstrates That Hypoxia-activated Prodrugs Differ in POR Dependence. Journal of Biological Chemistry. 288(52). 37138–37153. 18 indexed citations

11.

Patel, Kashyap, Maria R. Abbattista, Christopher P. Guise, et al.. (2013). The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104. Frontiers in Oncology. 3. 263–263. 40 indexed citations

12.

Prosser, Gareth A., Janine N. Copp, Alexandra M. Mowday, et al.. (2013). Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A. Biochemical Pharmacology. 85(8). 1091–1103. 43 indexed citations

13.

Swe, Pearl M., Janine N. Copp, Christopher P. Guise, et al.. (2012). Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954. Biochemical Pharmacology. 84(6). 775–783. 25 indexed citations

14.

Meng, Fanying, James Evans, Monica Banica, et al.. (2011). Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302. Molecular Cancer Therapeutics. 11(3). 740–751. 160 indexed citations

15.

Guise, Christopher P., Maria R. Abbattista, Rachelle S. Singleton, et al.. (2010). The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3. Cancer Research. 70(4). 1573–1584. 141 indexed citations

16.

Li, Shuyu, Robert A. Spooner, Christopher P. Guise, et al.. (2010). Folding-competent and Folding-defective Forms of Ricin A Chain Have Different Fates after Retrotranslocation from the Endoplasmic Reticulum. Molecular Biology of the Cell. 21(15). 2543–2554. 43 indexed citations

17.

Singleton, Rachelle S., Christopher P. Guise, Dianne M. Ferry, et al.. (2009). DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity. Cancer Research. 69(9). 3884–3891. 60 indexed citations

18.

Jaberipour, Mansooreh, Christopher P. Guise, Jane I. Grove, et al.. (2009). Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: Effects of combining beneficial single mutations. Biochemical Pharmacology. 79(2). 102–111. 27 indexed citations

19.

Guise, Christopher P., et al.. (2007). Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle. Gene Therapy. 14(8). 690–698. 17 indexed citations

20.

Grove, Jane I., Andrew L. Lovering, Christopher P. Guise, et al.. (2003). Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.. University of Birmingham Research Portal (University of Birmingham). 63(17). 5532–7. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact